PV-10

DRUG2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Provectus Biopharmaceuticals, Inc.

Conditions

Melanoma

Phase 1

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

CompletedNCT01760499

H. Lee Moffitt Cancer Center and Research InstituteMelanoma

Start: 2013-01-24End: 2017-04-30Updated: 2017-04-19

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Provectus Biopharmaceuticals, Inc.Melanoma

Start: 2015-10-31End: 2025-04-30Updated: 2023-11-21

Related Papers

Abstract 1121: Identification and <i>in vivo</i> validation of unique anti-oncogenic properties and mechanisms involving protein kinase signalling and autophagy mediated by the investigational new agent PV-10

Cancer Research2022-06-15

Pre-clinical evaluation of PV-10 for <i><i>in vitro</i></i> anti-tumor activity in refractory and high-risk adult solid tumors.

Journal of Clinical Oncology2021-05-20

Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.

Journal of Clinical Oncology2019-05-2020 citations

In vitro and xenograft anti-tumor activity, target modulation and drug synergy studies of PV-10 against refractory pediatric solid tumors.

Journal of Clinical Oncology2018-05-201 citations

Intralesional rose bengal for treatment of melanoma.

Journal of Clinical Oncology2016-05-202 citations

Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions.

Journal of Clinical Oncology2014-05-2018 citations